Title	COX-2 Blockade in Cancer Prevention and Therapy [electronic resource] / edited by Randall E. Harris
Imprint	Totowa, NJ : Humana Press : Imprint: Humana Press, 2003
Connect to	http://dx.doi.org/10.1007/978-1-59259-302-6
Descript	X, 371 p. online resource

The discovery that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have notable antineoplastic properties has revolutionized cancer research. In COX-2 Blockade in Cancer Prevention and Therapy, a panel of leading experts chronicles the evidence for the chemopreventive and therapeutic effects of cyclooxygenase-2 (COX-2) inhibitors against virtually all forms of cancer and presents exciting new opportunities for the use of COX-2 blockade in their prevention and treatment. These highly experienced authors elucidate the process by which COX-2 inhibitors interrupt prostaglandin biosynthesis and cancer development, examine the positive epidemiological effects of such NSAIDs as aspirin and ibuprofen on various cancers, and demonstrate through animal models that NSAIDs inhibit a variety of malignant neoplasms in vivo. They also present genetic models confirming the critical role of COX-2 in carcinogenesis and discuss how its molecular biology modulates carcinogenesis via such processes as mutagenesis, cell division, angiogenesis, cell differentiation, and apoptosis. In addition, the authors review the clinical applications of selected NSAIDs that are immediately relevant to cancer prevention and control and outline the future prospects of COX-2 blocking agents. Comprehensive and up-to-date, COX-2 Blockade in Cancer Prevention and Therapy demonstrates how COX-2 inhibitors and other NSAIDs reduce the risk of most cancers and provides cancer investigators today with a clear and authoritative guide to the development of novel agents with significant antineoplastic properties

I. Historical Perspectives -- l Dietary Fatty Acids, COX-2 Blockade, and Carcinogenesis -- 2 Historical Aspects of COX-2: Cloning and Characterization of the cDNA, Protein and Gene -- II. Epidemiology of NSAIDS and Cancer -- 3 Epidemiology of Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer -- 4 Epidemiology of Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs: Extension of the Dietary Fat Hypothesis of Breast Cancer -- III. Animal Models of Carcinogenesis -- 5 Role of Synthetic and Naturally Occurring Cyclooxygenase Inhibitors in Colon Cancer Prevention -- 6 Chemoprevention of Breast Cancer by Nonsteroidal Anti-Inflammatory Drugs and Selective COX-2 Blockade in Animals -- 7 The Role of Cyclooxygenase-2 in the Prevention and Therapy of Lung Cancer -- 8 Nonsteroidal Anti-Inflammatory Drugs, Prostaglandins, and Apc-Driven Intestinal Tumorigenesis -- 9 Cyclooxygenase-1 and Cyclooxygenase-2 Knockout Mice Provide Insights into Beneficial and Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs -- IV. Molecular Biology of CXO -- 10 Cyclooxygenase-2, Prostaglandins, and Colorectal Carcinogenesis -- 11 Regulation of Expression and Potential Carcinogenic Role of Cyclooxygenase-2 -- 12 Cyclooxygenase-2 and Cancer -- 13 Interactions of Cyclooxygenase and Aromatase Pathways in Normal and Malignant Breast Cells -- 14 Association of COX-2 and PPARs in Carcinogenesis and Chemoprevention -- 15 Carcinogenesis Involving Cyclooxygenase and Lipoxygenase -- V. Clinical Applications -- 16 The Development of Drugs that Target Cyclooxygenase-2 -- 17 Chemoprevention of Cancer by NSAIDs and Selective COX-2 Blockade -- 18 Potential for Inhibitors of Cyclooxygenase-2 to Enhance Tumor Radioresponse -- 19 Potential Role of NSAIDs and COX-2 Blockade in Cancer Therapy -- 20 Cyclooxygenase-2 Blockade in Cancer Prevention and Therapy: Widening the Scope of Impact